While coverage of 13-F filings tends to focus on individual celebrity investors such as Michael Burry or Warren Buffett, or major banks, another important actor in the business world provided an update for its stock portfolio in early May: Alphabet (NASDAQ: GOOGL).
The document showed that between the fourth quarter (Q4) of 2025 and Q1 of 2026, Google increased the value of its holdings by as much as $1.5 billion despite decreasing the number of company stocks held by 3: from 29 to 26.
Simultaneously, it showed that the balance within the portfolio changed significantly, with an entirely new equity taking the top spot and accounting for as much as 26% of the total.
Google bought and sold these stocks in Q1, 2026
Specifically, Google appears to have developed entirely new positions in three companies: nearly 3.5 million shares of CME Group Inc (NASDAQ: CME), 3.1 million PayPal (NASDAQ: PYPL) shares, and just under 3.8 million shares of Ethos Technologies Inc (NASDAQ: LIFE).
On the flip side, the blue-chip technology giant completely cleared its stake in five firms: Repligen Corp (NASDAQ: RGEN), Fulcrum Therapeutics (NASDAQ: FULC), Quince Therapeutics (NASDAQ: QNCX), Exact Sciences Corp (NASDAQ: EXAS) – acquired by Abbott Laboratories on March 20, 2026 – GeneDx Holdings (NASDAQ: WGS), and DexCom (NASDAQ: DXCM).
Out of the sales, DXCM stock is notable for being by far the largest position cleared in its entirety at 1 million shares worth nearly $70 million, and RGEN stock for being by far the smallest: 383 shares worth $62,000.
In contrast, the smallest stake Google retained to the end of Q1, 2026, was the 915,705 shares of Tenaya Therapeutics (NASDAQ: TNYA) worth $631,000.
These are the top positions in the Q1 Google portfolio
Elsewhere, one new investment – CME – turned into Google’s biggest position at just over $1 billion worth of shares: 26% of the $4 billion portfolio. The previous top holding – AST SpaceMobile (NASDAQ: ASTS) – fell to third place at 19% despite Alphabet selling none of its 9 million ASTS shares.
In terms of incremental changes, the technology giant increased its Planet Labs (NYSE: PL) position by 10% and lowered its stake in Monte Rosa Therapeutics (NASDAQ: GLUE), Revolution Medicines (NASDAQ: RVMD), and Relay Therapeutics (NASDAQ: RLA) by 8%, 2%, and, finally, less than 1%, respectively.
Featured image via Shutterstock